

## Servier inaugurates a bioproduction plant in France to support the growth of its R&D programs

- A strategic unit that should enable innovative therapies to be developed more rapidly, particularly in the field of oncology
- A total investment of 86 million euros in Loiret contributing to strengthening innovation and French and European health sovereignty

**Gidy, Loiret, France, November 27, 2024** — Servier, an international and independent pharmaceutical group, today announced the inauguration of “Bio-S”, its first unit dedicated to the production of biological medicines from its R&D pipeline, located at its historic site in Gidy, Loiret.

The result of an investment of €86 million, this new bioproduction unit will enable Servier to produce active ingredients in France derived from living cells for its preclinical and clinical studies as well as sterile and injectable finished products, thus ensuring strategic autonomy for the Group’s clinical trials.

For the Group, having its own biotechnology unit will allow clinical proof of concept of biological medicines candidates to be provided more quickly. This agility will ultimately make it possible to accelerate the development of these innovative therapies and quickly make them available to patients. Biological medicines represent nearly 60% of treatments in development worldwide. However, France produces only 10% of those developed in Europe.

*“We have chosen to invest heavily in a bioproduction unit, in order to strengthen our commitment to accelerate therapeutic progress for the benefit of patients. While we have a pipeline of 61 research and development projects, 50% of which are of potential biological medicines candidates, this strategic investment illustrates our Group’s desire to consolidate its unique value chain in France and Europe, from research to industry, and is fully in line with our 2030 strategic objectives to make Servier a recognized and innovative player in oncology,”* states **Olivier Laureau, President of the Servier Group.**

Closely linked to Servier’s next-generation antibody center of excellence based in Denmark, Bio-S reinforces Servier’s ability to develop new precision treatments based on therapeutic antibodies, bispecific antibodies, and antibody-conjugated drugs (ACD) for patients with rare cancers.

**Claude Bertrand, Executive Vice-President in charge of Research and Development of the Servier Group adds:** *“Biological medicines represent a new generation of therapies,*

*based on a biological source as the raw material for the active ingredient. They are a major therapeutic innovation. By controlling our value chain from Research to Production, we put Servier in a unique position to develop innovative therapeutic solutions faster, one of the key issues for patients.”*

Bio-S has created around sixty direct jobs, also demonstrating Servier’s commitment to developing skills and expertise in the bioproduction sector in France. Servier is also a founding member of the France BioLead alliance and Campus Biotech Digital and actively participates in the development of the bioproduction sector in France, thus contributing to the attractiveness and competitiveness of the sector.

**Key figures for Bio-S, Servier Group’s bioproduction unit:**

- ✓ 10,000 m<sup>2</sup>
- ✓ 1,500 m<sup>2</sup> of clean room space
- ✓ Bio-reactors for from 15 milliliters to 200 liters for cell culture for bio-engineering activities, up to 500 and 2000 liters for clinical biomanufacturing GMP
- ✓ Aseptic filling in liquid form (vials or syringes) with capacities for lyophilization vials
- ✓ 60 employees
- ✓ A total investment of €130 million (Bio-S and CSU)
- ✓ An operational start expected during the second half of 2025

This day is also marked by the official launch of the extension work of the Clinical Support Unit (CSU), intended to manufacture of the Group’s experimental drugs. An additional investment of 43 million euros granted by the Group, also at its Gidy site in Loiret. Unique in Europe, Bio-S and CSU (a total of €130 million invested) bring together in one place all the expertise needed to ensure the clinical supply of biological medicines, from the clinical biological active ingredient to the distribution of clinical batches.

**About Servier**

Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs.

The 21,900 employees of the Group are committed to this shared vocation, a source of inspiration every day.

As a world leader in cardiology, Servier’s ambition is to become a focused and innovative player in oncology by targeting rare cancers. That is why the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology.

Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.

In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.

Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €5.3 billion in 2023.

More information on the new Group website: [servier.com](https://servier.com)

Follow us on social media: [LinkedIn](#), [Facebook](#), [Twitter](#), [Instagram](#)

